When did Xeljanz (tofacitinib) go generic?
Xeljanz has not had a widely available “generic” version in the way older small-molecule drugs usually do. Instead, the first true generic entry for tofacitinib depended on patent and exclusivity timelines and the specific country’s approvals.
Why isn’t it a straightforward “generic date” like other drugs?
Tofacitinib (Xeljanz) has faced long patent-protection and regulatory exclusivity constraints that can delay generic approval even after the drug’s original launch. That means the “generic availability date” can differ by market (US vs. EU vs. other countries) and by whether the product is an FDA-approved generic or an authorized branded alternative.
How to figure out the exact date you mean (US vs. other countries)
If you tell me which country (and whether you mean tablets, extended-release, or a specific strength), I can pinpoint the most relevant approval/launch timing for that market.
What to check if you’re looking in a pharmacy
When the first generic becomes available, you’ll typically see:
- “tofacitinib” (generic name) on the label, not “Xeljanz”
- an FDA (or local regulator) approved generic manufacturer/ANDA reference for US-style approvals
If you share your location (US, UK, Canada, EU country, etc.) and the formulation (Xeljanz immediate-release vs. Xeljanz XR), I’ll narrow it down to the most accurate “go generic” timeline.